Hormonal
GLP-1 receptor agonists (semaglutide, liraglutide, exenatide) significantly reduce body weight and improve glucose metabolism in non-diabetic obese individuals and those with prediabetes, often leading to normoglycemia.
For non-diabetic individuals with obesity or prediabetes, weekly GLP-1 injections (semaglutide 2.4 mg) can lead to significant weight loss (approx. 15%) and high rates of returning to normal blood sugar levels. This is more effective than lifestyle changes alone.
Exenatide-treated (10 mg SC with a 4-week 5 mg dose-initiation period) participants lost 5.1 + 0.5 kg from baseline versus 1.6 + 0.5 kg with placebo (P < .001) ... Consequently, after 24 weeks, 77% of patients with prediabetes returned to normoglycemia, compared with 56% of patients treated with placebo. ... Treatment with semaglutide was associated with sustained, clinically relevant (-14.9%) mean change in BW from baseline. ... 84.1% of participants in the semaglutide group who had prediabetes at baseline, as compared with 47.8% of participants in the placebo group with prediabetes reverted to normoglycemia.
Why this rating
Based on multiple large-scale randomized controlled trials (STEP, SCALE) with consistent positive outcomes.
Source
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović et al. · Journal of Cardiovascular Pharmacology and Therapeutics · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →